Stem cell infusions (with or without total body irradiation [TBI]):\r\n* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion, and no evidence of graft-versus-host disease (GVHD)\r\n* Autologous stem cell infusion including boost infusion: >= 42 days
Participants must be at least 100 days after the transplantation or a donor lymphocyte infusion
Donor lymphocyte infusion within 100 days prior to enrollment
Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.
Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible
Patients receiving a donor lymphocyte infusion within 4 weeks of planned T cell infusion
Patients receiving a donor lymphocyte infusion within 4 weeks of planned T cell infusion
Subjects who developed aGVHD after unplanned donor lymphocyte infusion.
TREATMENT WITH SJCAR19: Prior to planned SJCAR19 infusion, patients with a history of prior allogeneic HCT must be at least 3 months from HCT, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
Donor lymphocyte infusion (DLI) within 28 days prior to enrollment
Subjects must be at least 100 days from prior stem cell transplant (autologous or allogeneic) or donor lymphocyte infusion (DLI)
Donor lymphocyte infusion administered to treat relapse or loss of donor chimerism
Prior donor lymphocyte infusions (DLIs) are not necessary
Donor lymphocyte infusions (DLI) within 6 weeks of JCAR017 administration
Patients who have had donor lymphocyte infusion (DLI) within 8 weeks prior to registration
Donor lymphocyte infusion within 100 days prior to enrollment
Subjects must not have received a donor lymphocyte infusion (DLI) within 8 weeks prior to the first dose of study medication
Has received donor lymphocyte infusion (DLI) product within 6 weeks of CAR T cell infusion
High dose therapy with autologous hematopoietic cell infusion (At least 60 days from last infusion prior to first dose of tazemetostat)
ELIGIBILITY CRITERIA FOR T-CELL PRODUCT INFUSION: Absolute lymphocyte count < 500/ul or patient has received lymphodepleting chemotherapy administered at least 24 hours prior to T cell infusion
Patients who have received donor lymphocyte infusion (DLI) within 28 days of Viralym-A infusion.
Patients who have received donor lymphocyte infusion (DLI) within 28 days
Patients who have received donor lymphocyte infusion (DLI) within 28 days
No change in dosing of immunosuppressive agents in the 2 weeks preceding the naive T-cell depleted donor lymphocyte infusion
A commitment not to electively taper for a minimum of 60 days, the immunosuppressive medications ongoing at time of naive T-cell depleted donor lymphocyte infusion
Patients developing SR aGvHD after donor lymphocyte infusion (DLI) or after withdrawal of immunosuppression are eligible
Donor lymphocyte infusion within 8 weeks prior to treatment start if post-transplant
Logistical requirements:\r\n* Space available in infusion room\r\n* Outpatient infusion pump available if continuous infusion required\r\n* Case discussed with infusion room nursing staff
Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion or boost infusion: ?84 days after infusion and no evidence of graft versus host disease (GVHD)
Autologous stem cell infusion including boost infusion: ?42 days
Unplanned donor lymphocyte infusion (DLI) for residual or relapsed malignancy or mixed chimerism. DLI as part of the planned HCT protocol is allowed.
Less than 2 months following bone marrow or peripheral blood stem cell transplantation or treatment with donor lymphocyte infusion (DLI).
Donor lymphocyte infusion (DLI) is considered a reinduction attempt.
At least 4 weeks (from first dose) elapsed from donor lymphocyte infusion (DLI) without conditioning.
Patients with acute GVHD developing after a donor lymphocyte infusion.
Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusion
Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusion
The patient has, or accepts to have, an acceptable infusion device for infusion of melflufen
Donor lymphocyte infusion (DLI) within 28 days prior to enrollment
Donor lymphocyte infusion within 100 days prior to enrollment
Donor lymphocyte infusion within 12 wks prior to starting dose of AMG 592.
Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis
Stem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: ?84 days after infusion and no evidence of graft versus host disease; Autologous stem cell infusion including boost infusion: ?42 days
Patients may have had prior treatment for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), including lenalidomide; patient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entry; patients may also have had donor lymphocyte infusion if there is at least 60 days between donor lymphocyte infusion and study entry; patients on immunosuppression are also eligible
DONOR: Must consent to granulocyte-colony stimulating factor (G-CSF) (filgrastim) administration and leukapheresis for both PBSC allograft and subsequent donor lymphocyte infusion (DLI)
Subjects who received an unplanned (not part of the original transplant therapy plan) donor lymphocyte infusion.
Allogeneic cellular therapy: Donor lymphocyte infusions (DLI) are prohibited within 4 weeks prior to leukapheresis
Participant whose GvHD developed after donor lymphocyte infusion
The patient will need to be available for evaluation within 72 hours of symptoms of GVHD, occurring within 60 days of the planned donor lymphocyte infusion
No chemotherapy, RT, donor lymphocyte infusion (DLI) or biologic therapy for lymphoma at least 4 weeks prior to scheduled treatment
Patients who have received donor lymphocyte infusion (DLI) within 28 days of Viralym-C infusion.
Received donor lymphocyte infusion (DLI) within 28 days
Treatment with Epstein-Barr virus cytotoxic T lymphocytes, chimeric antigen receptor (CAR)-T cells directed against B cells, or unselected donor lymphocyte infusion (DLI) within 8 weeks of Cycle 1 Day 1
Patients may also have had donor lymphocyte infusion if there is at least 60 days between donor lymphocyte infusion and study entry
Anticipated planned donor lymphocyte infusion in the first 3 months post-SCT
Patients may have received a prior allogeneic hematopoietic stem cell transplant (alloHSCT) for any indication and from any donor; patients developing cGvHD after donor lymphocyte infusion (DLI) are also eligible
Received a donor lymphocyte infusion (DLI) or hematopoietic cell transplantation (HCT) within 3 months of enrollment
Planned use of prophylactic donor lymphocyte infusion (DLI) therapy
Donor lymphocyte infusion within 100 days prior
Patients who have received donor lymphocyte infusion (DLI) within 28 days
Patients whose GVHD developed after donor lymphocyte infusion (DLI)
Donor lymphocyte infusion in the preceding 100 days
Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
FOR THE 31 SUBJECTS ENROLLED IN YEAR 1: Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
No donor lymphocyte infusion (DLI) prior to day 100, and no plans for a DLI in the upcoming 30 days
Patients may have received no more than one donor lymphocyte infusion (DLI), DLI must have been administered > 6 weeks prior to enrollment on study, and no plans for a DLI in the upcoming 30 days
Donor lymphocyte infusions (DLI) within 6 weeks of JCAR017 administration
At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI) without conditioning.
